Biopharmaceutical News and Research

RSS

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram quantities of enzyme.

12 Oct 2010

BioSystem Development completes $978,000 investment round

BioSystem Development, a privately held life science analytics company, announces a recently completed investment round that raised $978,000 (USD) in funding. The proceeds will be used to expand manufacturing infrastructure and to launch new products into the biopharmaceutical development market.

12 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

ImaginAb and Imanet enter master service agreement for pre-clinical and clinical imaging

ImaginAb, Inc. and Imanet have signed a master service agreement for pre-clinical and clinical imaging. This agreement supports the development strategy for ImaginAb's pipeline of next generation diagnostic imaging agents based on recombinant antibody fragments. The Imanet™ network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept radiochemistry to clinical imaging, with more than 40 PET research tracers.

11 Oct 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.

11 Oct 2010

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference being held in Milan, Italy, October 8-12, 2010.

11 Oct 2010

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first subject has been dosed in the global phase III program of XIAFLEX® for the treatment of Peyronie's disease. Peyronie's disease is the development of scar tissue on the penis that can cause the penis to curve during erection, often interfering with or preventing intercourse and resulting in psychological distress or bother for the patient.

11 Oct 2010

Ipsen announces sale of shares in PregLem Holding to Gedeon Richter

Ipsen today disclosed that it has sold its shares in PregLem Holding SA to Gedeon Richter Plc, as have all PregLem's other shareholders.

11 Oct 2010

BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that it has begun to immunize subjects in a Phase IIa clinical trial of the Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine.

11 Oct 2010

VentiRx announces VTX-1463 trial results for allergic rhinitis treatment

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.

8 Oct 2010

ARCA receives European Patent for bucindolol based treatment for heart failure

ARCA biopharma, Inc. a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that the European Patent Office has issued a patent on methods of treating heart failure patients with bucindolol based on genetic targeting.

8 Oct 2010

Cyclacel announces completion of private placement sale

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today that it consummated its previously announced private placement to sell approximately $15.2 million of its units to several institutional investors, including the Special Situations Funds, for net proceeds of approximately $14.1 million after the deduction of offering expenses.

7 Oct 2010

Quintiles, SNUH announce clinical research partnership

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today celebrated its 10th year anniversary in South Korea by announcing a strategic alliance with the Seoul National University Hospital (SNUH) as part of its unique Prime Site program. SNUH is Quintiles' second Prime Site in Asia, adding to six other existing sites located in the United States, Europe and Africa.

7 Oct 2010

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Johnson & Johnson and Crucell N.V. today announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately euro 1.75 billion in a recommended cash tender offer.

6 Oct 2010

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

ACR Image Metrix, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, is pleased to announce a Phase III trial, conducted for Aegerion Pharmaceuticals, Inc., was published as an abstract in the online supplement of Atherosclerosis and presented at the 78th European Atherosclerosis Society Congress, which took place June 20-23, 2010, in Hamburg, Germany.

6 Oct 2010

DATATRAK receives consulting contract to provide clinical data management

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the award of a consulting contract with an existing global research-based biopharmaceutical client to provide clinical data management and trial design services.

5 Oct 2010

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.

5 Oct 2010

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

RHUCIN clinical trial results published in JACI journal

Santarus, Inc., a specialty biopharmaceutical company, today announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN (recombinant human C1 inhibitor, or rhC1INH), in the October issue of the peer reviewed Journal of Allergy and Clinical Immunology (JACI).

5 Oct 2010

Biopharmaceutical News and Research

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

BioSystem Development completes $978,000 investment round

Access highlights clinical benefits of MuGard at ESMO conference

ImaginAb and Imanet enter master service agreement for pre-clinical and clinical imaging

AVEO presents tivozanib Phase 2 study results at ESMO Congress

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Ipsen announces sale of shares in PregLem Holding to Gedeon Richter

BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study

VentiRx announces VTX-1463 trial results for allergic rhinitis treatment

ARCA receives European Patent for bucindolol based treatment for heart failure

Cyclacel announces completion of private placement sale

Quintiles, SNUH announce clinical research partnership

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

DATATRAK receives consulting contract to provide clinical data management

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Neuraltus achieves last patient out for NP001, NP002 studies

RHUCIN clinical trial results published in JACI journal

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News